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Amiodarone — thyroid — arrhythmia. Difficult cooperation  
between endocrinologist and cardiologist  
A patient with amiodarone-induced thyroid disturbances
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Należy cytować wersję pierwotną
Abstract
We present the case of a patient with atrial flutter (treated with cryoablation) and amiodarone-induced hypothyroidism 
(AIH). Administration of L-thyroxine supplementation triggered a recurrence of arrhythmia. This report shows how 
difficult it can be to treat a patient with AIH and how important it is to ensure cooperation between cardiologist and 
endocrinologist.
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Introduction
Amiodarone is a drug used in the treatment of supraventri-
cular arrhythmias, and in ventricular arrhythmias as a su-
pplement to electrotherapy. Thyroid dysfunction is a known 
side effect. In a patient with such complications, treatment 
becomes a challenge requiring close cooperation between 
a cardiologist and an endocrinologist, for whom the goals 
of treatment are not always convergent.
Case study
We present the case of a patient with atrial flutter treated 
with cryoablation, with thyroid dysfunction occurring after the 
inception of amiodarone therapy. The patient was an 85 year-
-old man with coronary disease, pharmacologically controlled 
hypertension, post-infarction heart failure, diet-controlled type 
2 diabetes, and hypercholesterolemia. The patient did not 
smoke and had a negative family history for atherosclerosis.
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At the age of 77, he suffered a ST-elevation myocardial 
infarction (STEMI): in urgent coronary angiography:
 — left coronary artery distally narrowed to 50–70%;
 — left anterior descending artery  with marginal changes 
narrowing the light to 70% on the entire course;
 — ostium of the circumflex artery of the coronary artery 
narrowed to 90%;
 — recessive right coronary artery, amputated ostia, pe-
riphery fills with its own collaterals.
Primary balloon angioplasty of the circumflex branch 
was performed. After three days, cardiogenic shock oc-
curred as a result of early restenosis. A stent was placed 
during re-angioplasty. Left ventricular ejection fraction 
(LVEF) assessed before discharge was 38%, and in the 
electrocardiogram (ECG) there were no deviations, except 
for the features of previous infarction.
A year later, a second myocardial infarction, non-ST-
-elevation (NSTEMI) occurred. In view of the sub-optimal 
effect of percutaneous treatment from the previous year, 
the patient was qualified for surgical revascularisation. An 
arterial bypass was implanted into the anterior descending 
branch and venous bypass to the circumflex branch. After 
the operation, the patient required an intraaortic balloon 
contrapulsation. At discharge, LVEF was 40%. The patient 
was prescribed:
 — bisoprolol 2.5 mg;
 — clopidogrel 75 mg;
 — atorvastatin 20 mg;
 — pantoprazole 20 mg;
 — acetylsalicylic acid 150 mg;
 — eplerenone 25 mg.
At the age of 79, paroxysmal atrial tachycardia followed 
by atrial flutter appeared for the first time. Due to the short- 
-term effectiveness of pharmacotherapy, the patient was 
qualified for interventional treatment. The electrophysio-
logical examination revealed an atrial flutter of 270/min. 
Cryoablation of the cavotricuspid isthmus was performed. 
After surgery, sinus rhythm was obtained with right branch 
bundle block and left anterior fascicular block. The thyroid 
hormone profile was assessed for the first time — all were 
normal [thyroid-stimulating hormone [TSH] 2.26 mlU/l, 
free triiodothyronine [fT3] 4.54 pmol/L, free thyroxine [fT4] 
21.14 pmol/L). Acenocoumarol was started.
At the age of 84, Holter ECG monitoring performed 
during the rehabilitation programme recorded elongation 
of the PQ interval, one episode of ventricular tachycardia 
(nine evolutions at a frequency of 144/min); and one 
episode of supraventricular tachycardia (three evolutions 
at a frequency of 120/min). Asymptomatic arrhythmias 
did not cause any changes in pharmacological treatment.
At the age of 85, Holter monitoring was repeated, 
which revealed two episodes of ventricular tachycardia: 
27 and six evolutions > 100/min, and seven episodes of 
supraventricular tachycardia (from three to six evolutions 
> 100/min). In view of the severity of the arrhythmia, it 
was decided to permanently use amiodarone 200 mg, 
while monitoring the thyroid function by an endocrinologist.
Six months after the amiodarone introduction, elonga-
tion of the PQ interval to 286 ms and QT interval to 526 ms 
were recorded (Figure 1). Therefore, the dose of bisoprolol 
was reduced to 2.5 mg, and amiodarone to 100 mg. In 
a follow-up study performed two months later, the reduced 
beta-blocker and amiodarone doses had shortened the PQ 
interval to 228 ms and the QT interval to 464 ms (Figure 2).
In a control ECG after six months, an extended PQ 
interval (304 ms), and an extended QT interval (514 ms) 
were observed. For this reason, the beta-blocker and amio-
darone doses were reduced again. After three months of 
Figure 1. Electrocardiogram (ECG) of the patient in April 2016: PQ interval 286 ms, QT interval 526 ms; bisoprolol 5 mg, amiodarone 200 mg. 
ECG recordings and measurements of QTc intervals were made using the ECG Cardiovit MS-12 blue from Schiller (Switzerland)
300
Folia Cardiologica 2019, vol. 14, no. 3
www.journals.viamedica.pl/folia_cardiologica
treatment with 1.25 mg bisoprolol and 50 mg amiodarone 
per day, in ECG the PQ interval was 274 ms and the QT 
interval was 488 ms.
At the next cardiology follow-up visit, the patient infor-
med a cardiologist that he was taking a new medicine from 
an endocrinologist and that he often felt fast palpitations. 
ECG revealed atrial tachycardia with 2:1 conduction. It 
turned out that L-thyroxine 25 μg/day was started due to 
the high TSH value of 28 mlU/l. Because TSH value was 
18 mlU/l, after the first month of therapy, the dose of L-thy-
roxine was escalated to 50 μg, which caused re-episodes 
of paroxysmal atrial tachycardia (Figure 3).
In the case described, the following therapeutic options 
were considered:
 — another ablation — the patient did not agree to re-
-treatment;
 — discontinuation of L-thyroxine — this carried the risks 
arising from hypothyroidism, which may be one of the 
causes of QT prolongation;
 — discontinuation of amiodarone — this was associated 
with a risk of worsening the patient’s arrhythmia.
Over the following months, the patient did not appear 
at the Cardiology Clinic due to a difficult family situation. 
It turned out that after six months he had discontinued 
Figure 2. Electrocardiogram of the patient in June 2016 after reduction of drug doses: PQ interval 228 ms, QT interval 464; bisoprolol 
2.5 mg, amiodarone 100 mg
Figure 3. Electrocardiogram of the patient after the start of 50 μg of L-thyroxine
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toxic effects of the drug on the thyroid gland or due to 
the presence of a large amount of iodine, which in some 
patients leads to the occurrence of hypothyroidism (AIH). 
Hyperthyroidism may occur as a result of iodine-induced 
uncontrolled hormone production. This occurs most often 
in patients with nodular goitre or a silent Graves-Basedow 
disease [type 1 amiodarone-induced thyroid toxicity (AIT)]. 
Type 2 hyperthyroidism is the result of destructive thyroiditis 
in the previously healthy thyroid gland [2]. The prognostic 
factors for the occurrence of thyroid intestinal disorders are 
unknown. Retrospective studies indicate that the predictive 
factor may be the serum ratio of desethylenedioquinone 
(DEA) — a drug metabolite — to amiodarone (AMD) [3]. In 
AIT cases, a higher DEA/AMD ratio was found than in AIH 
patients. Amiodarone is metabolised in the liver via CYP 
3A4 [4]. Therefore, the polymorphisms of this enzyme gene 
and its inducers may influence the probability of thyroid 
complications.
amiodarone on his own, and L-thyroxine was taken in a dose 
of 37.5 μg/day. Despite the discontinuation of amiodarone 
six months earlier, in the ECG the QTc interval was still 
extended to 554 ms, and sinus rhythm of 76/min was 
interrupted by episodes of tachycardia 114 /min. How-
ever, the patient did not feel any discomfort and refused 
hospitalisation to optimise his treatment because of the 
personal situation.
Discussion
In patients with cardiovascular diseases, post-amiodarone 
thyroid disorders are particularly dangerous because se-
vere hypothyroidism is one of the causes of prolonged QT 
interval which predisposes to severe ventricular arrhyth-
mias, whereas hyperactivity can exacerbate heart disease 
and increase mortality [1]. Disorders of thyroid function 
during the use of amiodarone may occur as a result of 
Streszczenie
W pracy przedstawiono leczonego krioablacją pacjenta z trzepotaniem przedsionków, u którego po włączeniu amiodaro-
nu wystąpiła niedoczynność tarczycy. Włączenie suplementacji L-tyroksyną wywołało nawrót arytmii. Przypadek ukazuje, 
jak trudne może być leczenie w takiej sytuacji oraz jak ważna jest ścisła współpraca kardiologa i endokrynologa podczas 
terapii poamiodaronowych zaburzeń czynności tarczycy.
Słowa kluczowe: amiodaron, trzepotanie przedsionków, niedoczynność tarczycy
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